Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ILK | Q13418 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032607 | 0.83 | SMN1; SMN2 (0.51) | GAASMN1; SMN2PIK3CANPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL458310 | 0.82 | SMN1; SMN2 (0.50) | GAASMN1; SMN2PIK3CANPC1CYP1A2 | |
| SCHEMBL10333137 | 0.80 | LMNA (0.54) | GAASMN1; SMN2SIGMAR1POLBALDH1A1 | |
| SCHEMBL10332821 | 0.74 | DRD4 (0.55) | POLBALDH1A1 | |
| SCHEMBL184869 | 0.73 | GAA (0.53) | GAASMN1; SMN2PIK3CAPOLBNPC1 | |
| SCHEMBL2400051 | 0.72 | L3MBTL1 (0.71) | GAASMN1; SMN2POLBKEAP1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL465775 | 0.72 | KCNJ1 (0.46) | GAASMN1; SMN2NPC1CYP1A2CYP3A4 | |
| SCHEMBL3717800 | 0.72 | SMN1; SMN2 (0.38) | GAASMN1; SMN2SIGMAR1PIK3CANPC1 | |
| SCHEMBL1662762 | 0.71 | POLB (0.46) | GAASMN1; SMN2SIGMAR1POLBNPC1 | |
| SCHEMBL10332624 | 0.70 | DRD4 (0.51) | SIGMAR1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875014-B1 | ANTI-MUCUS DRUGS AND USES THEREFOR | UNIV WASHINGTON (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-2114869-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | MAPK13, MAPK11, MUC1 | GAA 651/4885SMN1; SMN2 4868/4885SIGMAR1 826/4885 |
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | GAA 2306/4885SMN1; SMN2 2901/4885SIGMAR1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.